Showing 261-270 of 8879 results for "".
ASLMS New Beginnings Initiative
https://practicaldermatology.com/programs/practical-dermatology/aslms-new-beginnings-initiative/18188/In 2014, the American Society for Laser Medicine and Surgery started its New Beginnings initiative. Initially launched to benefit cancer survivors, ASLMS physicians volunteered to remove radiation tattoos pro bono. Recently, the ASLMS, under the leadership of its president Paul Friedman, MD, expandeClinical Conversations: A conversation with Dr Angela Lamb, a dermatologist and professor in New York, New York
https://practicaldermatology.com/programs/nemluvio-peer-network/clinical-conversations-a-conversation-with-dr-angela-lamb-a-dermatologist-and-professor-in-new-york-new-york/37237/Dr Angela Lamb discusses her approach to treating prurigo nodularis (PN) and atopic dermatitis (AD). She’ll explain how NEMLUVIO®, the first and only neuroimmune-targeted therapy that blocks IL-31RA, targets both immune and neuronal pathways and addresses chronic itch, inflammation, and barrier disrNoah Worcester 2024: Dr. Greenberg on the Society
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-greenberg-society/24588/Michael Greenberg, MD, president of the Noah Worcester Dermatological Society, speaks at the organization’s 2024 meeting about what makes the event special.New FDA Approval for AD
https://practicaldermatology.com/series/c-suite-chats/new-fda-approval-for-ad/29911/Phil Brown, MD, JD, Dermatologic Scientific Lead at Organon, talks about the importance of a new FDA-approved topical solution for treating atopic dermatitis.Weighing the Role of Network Meta-analysis for Choosing Biologic Therapies in Psoriatic Disease
https://practicaldermatology.com/programs/practical-dermatology/weighing-the-role-of-network-meta-analysis-for-choosing-biologic-therapies-in-psoriatic-disease/18189/There’s no paucity of studies for biologic therapies used to treat psoriatic disease, but the number of head-to-head trials comparing these agents is limited. Enter network meta-analysis, a statistical methodology that has emerged over the past few years to compare medication. Philip Mease, MD, a clUnmet Needs in Atopic Dermatitis
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/derm-hub/37140/Practical Dermatology Editorial Board member Todd Schlesinger, MD, a board-certified dermatologist and Mohs surgeon with Epiphany Dermatology in Charleston, South Carolina, talks about what he feels are the greatest unmet needs in atopic dermatitis.Radiesse Plus Launches, AAD Convenes, NPF Registry Begins
https://practicaldermatology.com/topics/psoriasis/dermwiretv-radiesse-plus-launches-aad-convenes-npf-registry-begins--epesurag/18939/In this edition of DermWireTV: Merz Aesthetics launches Radiesse Plus with lidocaine for the treatment of facial wrinkles and folds and the National Psoriasis Foundation (NPF) launches new patient registry focused on patient safety. Plus, updates from the annual meeting of the American Academy of DeA Case Presentation of Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37154/Alina Bridges, DO, Director of Dermatopathology & Associate Professor in the Department of Dermatology and Anatomic Pathology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, presents a case study involving a patient who had been on multiple treatments to present prurituNoah Worcester 2024: Dr. Adams on Sports Dermatology
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-adams-sports-dermatology/24584/Brian Adams, MD, MPH, summarizes his lecture on treating professional athletes at the 2024 Noah Worcester Dermatological Society meeting.DermWireTV: Novan EPI Acquisition, Champions for Change Gala, Mt. Sinai Alopecia Center
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-novan-epi-acquisition-champions-for-change-gala-mt-sinai-alopecia-center/20070/EPI Health is now a Novan company; the combined company will employ approximately 100 staff. Novan’s lead candidate, berdazimer gel 10.3%, performed well in a phase 3 study for the treatment of molluscum contagiosum. The Skin Cancer Foundation is gearing up for its signature fundraising event: The C